TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1907241
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (thrombolytic therapy)
Study: 6809158
Drug: Heat-stable measles
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable measles vaccine; stored unreconstituted at 37 degrees C for 14 days
Study: 6809158
Drug: Heat-stable measles
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable measles vaccine; reconstituted and stored at 25 degrees C for 48 hours and at 37 degrees C for at least four hours
Study: 6809158
Drug: Conventional measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional measles vaccines
Study: 28683994
Drug: Intravenous methylprednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylprednisolone, 250 mg at anesthetic induction and 250 mg at initiation of CPB (n=44)
Study: 25712416
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg the day before PCI and 40 mg 2-4 h before PCI)
Study: 25712416
Drug: Low-dose statins
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statins
Study: 23811624
Drug: Ultrasound-guided caudal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided caudal block with 8 ml of 0.3% ropivacaine and 100 µg of fentanyl
Study: 22066975
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n = 40) performing daily exercise with weekly load increase for 3 months
Study: 18271691
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (LCD) with yogurt enriched by low doses of n-3 PUFA (n-3 LCD)
Study: 9351414
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA
Study: 9351414
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA + PCB
Study: 9351414
Drug: GA without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GA without PG treatment
Study: 9351414
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively
Study: 30518237
Drug: Oral language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral language training
Study: 25767372
Drug: rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (20 mg/day) + valsartan (160 mg/day)
Study: 18441375
Drug: Nortriptyline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline plus nicotine replacement therapy
Study: 18441375
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nicotine replacement therapy
Study: 25749306
Drug: Nortriptyline-Morphine Combination
Normalized name: morphine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline-Morphine Combination
Study: 19929666
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of local anaesthetic
Study: 17180619
Drug: L: ‐tryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: L: ‐tryptophan (Trp)
Study: 9644320
Drug: TAT-59 (miproxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAT-59 (miproxifene phosphate) 20 mg orally for over 12 weeks
Study: 9644320
Drug: Tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen citrate (TAM) 20 mg orally for over 12 weeks
Study: 8159440
Drug: Hyperglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (blood glucose elevated to 12 mmol/l for 0.5 h and kept at that level for 2.5 h)
Study: 8159440
Drug: Euglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (blood glucose kept at 6 mmol/l for 3 h)
Study: 30256811
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D (10,000 IU/day)
Study: 30256811
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D (10,000 IU/day) in younger participants (ages 52-66)
Study: 27178513
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD) plus high dosage of betahistine (HDBH)
Study: 22430270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TET2(mut) and/or IDH(mut)
Study: 20332125
Drug: Omnitrope 3.3
Normalized name: Omnitrope 3.3 MG/ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnitrope 3.3 mg/ml solution
Study: 20332125
Drug: Omnitrope 6.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnitrope 6.7 mg/ml solution
Study: 20332125
Drug: Omnitrope 5
Normalized name: Omnitrope 5 Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnitrope 5 mg/ml powder
Study: 20332125
Drug: Genotropin 5
Normalized name: Genotropin 5 MG/ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin 5 mg/ml powder
Study: 15659145
Drug: Everolimus 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3.0 mg/d
Study: 12617381
Drug: Additional upper
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional upper limb physiotherapy (115 minutes, twice per day)
Study: 12617381
Drug: Wrist extension
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist extension measurement (twice daily with an electrogoniometer for 3-4 weeks)
Study: 10669898
Drug: Diclofenac injection
Normalized name: diclofenac Injection
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac injection (75 mg)
Study: 10669898
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of diclofenac (suppository and injection)
Study: 26922827
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) for 4 weeks
Study: 23243977
Drug: Rotation/Oscillation power
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotation/Oscillation power toothbrush (Oral‐B Triumph with SmartGuide)
Study: 18520610
Drug: Thrombin receptor
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin receptor activating peptide-induced platelet aggregation
Study: 2197345
Drug: Both strains
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both strains (highest doses)
Study: 24015984
Drug: Internet-based smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based smartphone application for self-control training (modified Stroop-task) delivered daily over 4 weeks
Study: 15849809
Drug: Proglumide treatment
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide treatment group (0.4 g proglumide thrice daily for more than 5 years)
Study: 12745495
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal nicotine (OT‐NIC) lozenge (4 mg)
Study: 11056094
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors or AT1-R antagonists
Study: 4034622
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg methylphenidate hydrochloride (Ritalin)
Study: 4034622
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methylphenidate hydrochloride (Ritalin)
Study: 4034622
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methylphenidate hydrochloride (Ritalin)
Study: 30382891
Drug: Personalized dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized dosage of morphine during the procedure when VAS ≥4
Study: 30382891
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine intravenously, followed by 10 mg of morphine subcutaneously 30 min before surgery (Control group)
Study: 26808848
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of citrulline-malate (CM)
Study: 22458601
Drug: Hawthorn extract
Normalized name: hawthorn extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hawthorn extract (1000 mg, 1500 mg, and 2500 mg)
Study: 8580690
Drug: Chinese medicinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicinal herbs and chemotherapy on the first postoperational day
Study: 8580690
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment two weeks later (Control)
Study: 384024
Drug: 2 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg. butorphanol
Study: 384024
Drug: 4 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg. butorphanol
Study: 384024
Drug: 80 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg. meperidine
Study: 19467415
Drug: Tongue base
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue base suspension
Study: 19467415
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients (tongue base suspension)
Study: 17612946
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg/day (bedtime dosing)
Study: 17612946
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg/day (bedtime dosing)
Study: 17612946
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (bedtime dosing)
Study: 17612946
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg/day (morning dosing)
Study: 11750840
Drug: Oral topotecan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan, 2.3 mg/m(2)/day for 5 days every 21 days
Study: 11750840
Drug: Intravenous topotecan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous topotecan, 1.5 mg/m(2)/day for 5 days every 21 days
Study: 8984044
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PRP-T vaccine
Study: 8984044
Drug: Associated with
Normalized name: Blood group antigen associated with but not included in MNS system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associated with DPT vaccine
Study: 7448509
Drug: Antiseptic skin
Normalized name: Antiseptic Skin Cleanser
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiseptic skin preparation and daily care of the cannula site
Study: 7448509
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin preparation before or after cannula insertion
Study: 3539614
Drug: Tiapamil 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil 800 mg
Study: 11213009
Drug: Two percent
Normalized name: LIDOCAINE HYDROCHLORIDE 20 mg in 1 mL TOPICAL SPRAY [Lidotral Two Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two percent lignocaine gel
Study: 11213009
Drug: Inert gel
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert gel (placebo)
Study: 29191649
Drug: 0.375% ropivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% ropivacaine, 20 mL plus 1 μg/kg of dexmedetomidine (group RD)
Study: 29191649
Drug: 0.375% ropivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% ropivacaine, 20 mL only (group R)
Study: 21438413
Drug: Pingchuan water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingchuan water decoction (one tie per day, in four to six-divided doses for eight weeks)
Study: 21438413
Drug: Montelukast Sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast Sodium tablets (4 mg for 2-5 years old or 5 mg for 6-14 years old, once every night before sleeping for eight weeks)
Study: 17682119
Drug: Glucosamine (500
Normalized name: poly(N-acetyl, N-arginyl)glucosamine (50000-80000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (500 mg orally three times daily for 2 weeks)
Study: 17682119
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg orally three times daily for 2 weeks)
Study: 10426383
Drug: 24-h Acipimox
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h Acipimox (250 mg/4 h)
Study: 2124986
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms plasma vaccine Pasteur (containing 1% pre-S2)
Study: 2124986
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms plasma vaccine MSD (no pre-S2)
Study: 21972820
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 110 mg twice daily
Study: 21972820
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg twice daily
Study: 21972820
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 75 mg twice daily (simulated for severely renally impaired patients)
Study: 11350844
Drug: Intramuscular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gold (GST)
Study: 9394106
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulfate (3 x 1 g/day)
Study: 7699154
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg i.v. OD for 4 days)
Study: 7699154
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with teicoplanin (800 mg i.v. OD) and netilmicin (300 mg i.m. OD)
Study: 7699154
Drug: Thymostimulin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (70 mg i.m. OD for the first month and every other day thereafter until discharge)
Study: 31188232
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction group (n = 17)
Study: 31188232
Drug: Dose maintenance
Normalized name: XCOPRI 250mg Daily Dose Maintenance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose maintenance group (n = 18)
Study: 19201696
Drug: tamsulosin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.8 mg once daily (QD)
Study: 19201696
Drug: alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 10 mg QD
Study: 8777471
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Placebo
Study: 8777471
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + HCTZ 6.25 mg
Study: 8777471
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + HCTZ 12.5 mg
Study: 8777471
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + HCTZ 25 mg
Study: 1538443
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (20 micrograms/ml)
Study: 1538443
Drug: Papaverine hydrochloride
Normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine hydrochloride (30 mg/ml)
Study: 17823448
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d of 78% active CLA isomers (3.2 g/d: 39.2% cis‐9,trans‐11 and 38.5% trans‐10,cis‐12)
Study: 17823448
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d of safflower oil (placebo)
Study: 17823448
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d of 78% active CLA isomers
Study: 10709412
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III drugs (sotalol and amiodarone)
Study: 2183505
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment with cyclosporin A (CSA) at a dosage of 2.5 mg/kg/d for 10 weeks
Study: 2183505
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of cyclosporin A (CSA) in 1/5/10% gel and ointment
Study: 31079328
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg of chromium picolinate (CrPic) supplementation per ewe (T1)
Study: 31079328
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg of CrPic per ewe (T2)
Study: 31079328
Drug: 0.30 mg
Normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg of CrPic per ewe (T3)
Study: 31079328
Drug: 0.45 mg
Normalized name: urea 0.45 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg of CrPic per ewe (T4)
Study: 29803838
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (through-the-scope clips and thermal therapy plus injection with diluted adrenaline)
Study: 1662376
Drug: Monoclonal anti-CD3
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal anti-CD3 antibody
Study: 7049955
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination of neomycin, cephaloridin, polymyxin B or E and nystatin or amphotericin B
Study: 30724002
Drug: Licogliflozin 150
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 150 mg q.d. for 12 weeks
Study: 30724002
Drug: Licogliflozin 300
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 300 mg single dose prior to OGTT
Study: 30724002
Drug: Licogliflozin 15
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 15 mg q.d. for 14 days
Study: 29871676
Drug: Data on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data on drug therapy, utilization of health services, and medical expenses
Study: 25985582
Drug: Letosteine (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letosteine (50mg thrice daily)
Study: 25985582
Drug: Ambroxol hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol hydrochloride (30mg thrice daily)
Study: 17145784
Drug: Ofloxacin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (20 mg/kg/day for 7 days)
Study: 17145784
Drug: Ofloxacin-Azithromycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin-Azithromycin (15 mg/kg/day of ofloxacin for 7 days and 10 mg/kg/day of azithromycin for the first 3 days)
Study: 17145784
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day for 7 days)
Study: 15807195
Drug: Statins (HMG-CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (HMG-CoA reductase inhibitors)
Study: 12113133
Drug: Irradiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation and chemotherapy
Study: 8056571
Drug: Alternate Treatment
Normalized name: Target Alternate Site Lancet 26G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate Treatment Control (ATC)
Study: 2468913
Drug: Verapamil (VER,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (VER, 240 mg/day)
Study: 2468913
Drug: Nifedipine (NIF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (NIF, 40 mg/day)
Study: 21070775
Drug: Peginterferon and
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon and ribavirin therapy
Study: 9242972
Drug: Cafestol (61-64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafestol (61-64 mg/day)
Study: 9242972
Drug: Cafestol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafestol (60 mg/day) and kahweol (48-54 mg/day)
Study: 28983994
Drug: HIT+β2 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIT+β2 A (daily inhalation of β2 ‐agonist terbutaline, 4 mg dose-1)
Study: 28983994
Drug: HIT (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIT (high intensity training without β2 ‐agonist)
Study: 22621750
Drug: Short-term adjunctive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term adjunctive subantimicrobial dose doxycycline (SDD)
Study: 19546674
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL 0.25% bupivacaine
Study: 15336473
Drug: Combined typhoid
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined typhoid fever/HAV vaccine (3 batches)
Study: 12575377
Drug: Shenqi tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi tablet (SQT)
Study: 2723122
Drug: Slow-release potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release potassium citrate tablets (60 meq)
Study: 2723122
Drug: Rapid-release liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-release liquid potassium citrate preparation (60 meq)